Markets
Tendies
@tendies
Bought APLT
Shares
down -27.26%
At 0.95, Exited 0.69
I'm looking at APLT since it's a biotech making strides for a rare disease treatment. The FDA's issues seem fixable, and if they manage to appeal succ...
Read
More
Thesis
I'm looking at APLT since it's a biotech making strides for a rare disease treatment. The FDA's issues seem fixable, and if they manage to appeal successfully, this stock could shoot up significantly. I believe there's a strong upside potential here that I don't want to miss.
Go back
Scalp
@scalpgan...
Bought APLT
Shares
down -17.06%
At 2.11, Exited 1.75
I'm watching APLT closely with an entry point above $2.30. I see a solid potential to reach targets of $2.50 to $2.75, while managing risk with a stop...
Read
More
Thesis
I'm watching APLT closely with an entry point above $2.30. I see a solid potential to reach targets of $2.50 to $2.75, while managing risk with a stop-loss at $2.15.
Go back
Mark
@markmast...
Bought APLT
Calls
down -20.0%
At 0.62, Exited 0.5
Contract:
2.5 Strike Call for
Apr 17
Darkpool reversal
Thesis
Darkpool reversal
Go back
RBC
@rbc_capi...
Shorted APLT
Shares
up 41.82%
At 2.2, Exited 1.28
Given the recent FDA updates regarding govorestat and the subsequent surge in Applied Therapeutics' stock, I anticipate that the stock is likely to fa...
Read
More
Thesis
Given the recent FDA updates regarding govorestat and the subsequent surge in Applied Therapeutics' stock, I anticipate that the stock is likely to face downward pressure as investors react to the anticipated correction following this spike. Thus, I believe APLT presents a strong shorting opportunity.
Go back
Long
@long_gam...
Bought APLT
Shares
down -9.31%
At 9.45, Exited 8.57
With the FDA decision on November 28th looming, I see a strong potential for APLT to surge if approval is granted. The market might not fully price th...
Read
More
Thesis
With the FDA decision on November 28th looming, I see a strong potential for APLT to surge if approval is granted. The market might not fully price this in yet, and I believe there’s significant upside in the coming weeks.
Go back
